ArticleVaccines2022

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab.

Tjalf Ziemssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.